Fellowship · Portland, OR
Sponsored by Oregon Health & Science University (OHSU Health)
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
The Lancet. Neurology · 2023 · 236 citations · Nizar Chahin
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
Neurology · 2024 · 70 citations · Amy Harper
Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
JAMA neurology · 2022 · 114 citations · Amy Harper
Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.
Journal of neuromuscular diseases · 2022 · 50 citations · Amy Harper
Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study.
Journal of neuromuscular diseases · 2023 · 33 citations · Amy Harper
Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis.
Annals of clinical and translational neurology · 2025 · 14 citations · Nizar Chahin
Findings from the Longitudinal CINRG Becker Natural History Study.
Journal of neuromuscular diseases · 2024 · 9 citations · Amy Harper
Strengths and Opportunities: Clinicians' Perspectives on Palliative Care for Amyotrophic Lateral Sclerosis (ALS) in the United States.
Muscle & nerve · 2025 · 6 citations · Noona Leavell